IGC Pharma Inc (IGC) News

https://finance.yahoo.com/news/igc-pharma-named-top-15-133000474.html

https://www.biospace.com/press-releases/igc-pharma-names-igc-ad1-phase-2-clinical-trial-for-alzheimers-agitation-calma-and-expands-recruitment-strategy As of January 8 2025

Now there trying to scare people out of there shares. There’s more buys than sells but the price is dropping. I see this going up a lot higher. I’m just holding.

IGC...4138...🥳Off the 3897 Alert...

georgie18

Member Level
Re: None

Wednesday, December 11, 2024 1:17:54 PM

Post#
667553
of 667765
IGC...3897...🥳Scaling in here... New trials to evaluate IGC-AD1's potential impact on amyloid plaque, tau tangles, and cognitive decline in Alzheimer's diseaseExpanded research positions IGC-AD1 as a potential treatment targeting the underlying disease pathology of Alzheimer's

POTOMAC, MARYLAND / ACCESSWIRE / December 2, 2024 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") announced today an expansion of its clinical research program for IGC-AD1, an investigational treatment for Alzheimer's disease. Building on Phase 2 interim results demonstrating reductions in agitation and cognitive improvement, the Company is initiating new trials to evaluate IGC-AD1's potential as a disease-modifying therapy.

The expanded research will explore how IGC-AD1's dual-action mechanism-combining anti-neuroinflammatory properties with amyloid- and tau-targeting effects-may slow the progression of Alzheimer's disease. These trials will evaluate critical outcomes, including cognitive function and biological markers associated with Alzheimer's, such as amyloid and tau levels, at multiple time points. Building on previously announced preclinical data showing IGC-AD1's impact on amyloid plaques and spatial memory, these investigations aim to explore its potential to influence key pathological features of Alzheimer's disease.

"We plan to initiate a new Phase 2 clinical trial for IGC-AD1 in 2025," said Ram Mukunda, CEO of IGC Pharma. "The trial underscores our commitment to advancing IGC-AD1 as a potential disease-modifying therapy for Alzheimer's. Cognitive decline is one of the most devastating aspects of Alzheimer's, severely impacting patients' memory, attention, and reasoning. By focusing on cognitive outcomes and underlying disease mechanisms such as amyloid plaques and tau tangles, we aim to address the critical unmet needs of patients and caregivers. This subsequent research phase is a significant step forward in delivering innovative treatments to those who need them most.

These new trials represent a pivotal step in advancing IGC-AD1 as a transformative Alzheimer's treatment. By exploring its potential as a disease-modifying therapy, we aim to create opportunities for strategic partnerships and licensing with major pharmaceutical companies. Our vision is to deliver innovative therapies that address the immense challenges faced by patients and caregivers while generating substantial value for our investors."

IGC...3897...🥳Scaling in here... New trials to evaluate IGC-AD1's potential impact on amyloid plaque, tau tangles, and cognitive decline in Alzheimer's diseaseExpanded research positions IGC-AD1 as a potential treatment targeting the underlying disease pathology of Alzheimer's

POTOMAC, MARYLAND / ACCESSWIRE / December 2, 2024 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") announced today an expansion of its clinical research program for IGC-AD1, an investigational treatment for Alzheimer's disease. Building on Phase 2 interim results demonstrating reductions in agitation and cognitive improvement, the Company is initiating new trials to evaluate IGC-AD1's potential as a disease-modifying therapy.

The expanded research will explore how IGC-AD1's dual-action mechanism-combining anti-neuroinflammatory properties with amyloid- and tau-targeting effects-may slow the progression of Alzheimer's disease. These trials will evaluate critical outcomes, including cognitive function and biological markers associated with Alzheimer's, such as amyloid and tau levels, at multiple time points. Building on previously announced preclinical data showing IGC-AD1's impact on amyloid plaques and spatial memory, these investigations aim to explore its potential to influence key pathological features of Alzheimer's disease.

"We plan to initiate a new Phase 2 clinical trial for IGC-AD1 in 2025," said Ram Mukunda, CEO of IGC Pharma. "The trial underscores our commitment to advancing IGC-AD1 as a potential disease-modifying therapy for Alzheimer's. Cognitive decline is one of the most devastating aspects of Alzheimer's, severely impacting patients' memory, attention, and reasoning. By focusing on cognitive outcomes and underlying disease mechanisms such as amyloid plaques and tau tangles, we aim to address the critical unmet needs of patients and caregivers. This subsequent research phase is a significant step forward in delivering innovative treatments to those who need them most.

These new trials represent a pivotal step in advancing IGC-AD1 as a transformative Alzheimer's treatment. By exploring its potential as a disease-modifying therapy, we aim to create opportunities for strategic partnerships and licensing with major pharmaceutical companies. Our vision is to deliver innovative therapies that address the immense challenges faced by patients and caregivers while generating substantial value for our investors."

https://finance.yahoo.com/news/igc-pharma-expands-drug-portfolio-120000131.html

Looks like Bradbury is unleashing some of its shares into the market

On March 22, 2024, the Company entered into a Share Purchase Agreement (the "SPA") with Bradbury, subject to the terms and subject to the conditions set forth in the SPA. The investment is for approximately $3 million in gross proceeds at the March 21, 2024, closing price of $0.34. The funds will support general corporate purposes and the Company's advancement of its investigational medicines including IGC-AD1.

The completion of the private placement is subject to customary closing conditions, including approval by the NYSE. Under the terms of the SPA, IGC will issue 8,823,529 shares of common stock. The shares are unregistered and are not immediately tradable.

Vamos a ver quien esta correcto


We will see who is right.

Creo que esta todo claro , nos vamos otra vez para abajo , lo que decian que iriamos a los 2 o mas nada de nada

Creo que entre $2 y $6 por ahora, si algo mas paso vamos hacer nuevo target del precio.

Solo es mi idea nada mas

Translation: I think between $2 to $6 unless something more happens, then would have to pick a new target.

JMO

Hola , hasta donde cree que puede llegar ? he visto que la sigue y esta muy activo en con los mensajes . Gracias

IGC HERE COMES .80C

IGC...READY FOR 80C

IGC..TRENDING IN THE 70S NOW

that was quite the pop, indeed!

IGC after hours pop

IGC...BREAKING OUT

IGC...GET OUT OF THE WAY ARCA...YA MAGGOT

IGC...BIO BEAST SETTING UPI TO BEAST

Yes 🙌🏿✊🏿

Ohhhh it's so peaceful without ANY pumper on board - Love it when a stock moves without the hub.

So the private placement is already a done deal at .34 which is where I placed my first buy so this really shouldn't drop tomorrow but if it does I'll be ready to scoop up what I can at my down price bid already set.

LET' S SEE HOW THIS PLAYS TOMORROW.

Looks like peeps are starting to digest the possibilities $IGC presents. Great time to jump on board to see where this ride goes from here.

– Interim Data: Study Achieves Primary End Point Demonstrating Clinical and Statistically Significant Reductions Compared to Placebo in Agitation Associated with Dementia Due to Alzheimer’s Disease –

Potomac, MD, March 20, 2024 – IGC Pharma, Inc. (“IGC Pharma”, “IGC”, or the “Company”) (NYSE American: IGC) today announced the results of an interim analysis of its ongoing Phase 2 trial investigating IGC-AD1 as a treatment for Agitation in dementia from Alzheimer’s Disease (“AAD”).

The interim data demonstrates a clinical and statistically significant reduction in agitation compared to placebo in patients with Alzheimer’s disease, indicating strong therapeutic potential for IGC-AD1.

The study’s primary goal is to assess the change in AAD after six weeks using a standard scale, the Cohen Mansfield Agitation Inventory (“CMAI”). Based on interim data, patients taking IGC-AD1, on average, experienced a more significant reduction in agitation scores compared to those on placebo, and the positive effects were observed as early as week two of the trial.

I have my target entry point - let's see if it hits.

Positive news out on drug candidate

Looking to pick up a starter here

Board needs a name change to reflect the new operations.

All these months i never understood WHO was propping these bs shares up over $1

Now it makes sense

.45 of them

Not in this, but had a watch on it, have low $8's in GRWG

Yes!, with or without the vote Cannabis/Hemp sector is ripe for a breakout that is what is happening,

the legalization news just came and it is going to add more fuel to the huge breakout!..

Big Vote next week, many movers in Sector

IGC breakout alert and 10% move up, just the ignition to the rally!? Isn't that a spot on "breakout alert" or what?. Well, almost all (more than 90% of my alerts) goes through a spot on results!..


Target price: $1.10, $2 and $5, all these are near term to short term targets spanning days, weeks to just couple of months!.

maintained a few small numbers for a long time, yesterday I nailed it when I saw the bottom!!..this will skyrocket for sure, but people must do their own research DDs! and make use of the opportunity in breakouts!

I have no position here. It has been on my watch list for about a decade

Agree with your second half, scammer CEO, but the company came long way now, he seems to be still on top of the management, but sales, products and research pipelines using cannabis/cbd are progressing, hard to believe but it is happening!.

the stupid stock price and poor performance is a industry/or Sector wide manipulation, nothing to do with how this co managed etc!.

and that is going to change now, as the sector reached a boiling point of exploding out of this manipulators control!, and every stock, good, bad, ugly will skyrocket...

you can take it or leave it, that is destined to happen!.

Enjoy the ride!

You do realize I've been here since Inception when this was an iron ore mining company with scam artist Ram Mukunda as CEO

Really!?...is that your discovery, time well spent and that "Nobody" is you alone or are there some more!?..

Nobody even knows what the hell this piece of shit company does

alright folks, check my breakout alert, previous post!.

Stop removing mods...

ihubs ridiculous removing mods got to stop, this is a bs policy! so much time is sucked up and go waste in putting up a board, morons remove it at their whims!.

Notorious "inverted Cup & Handle" is coming to an End!....IGC juar Bottomed!.

and that's got to change the status of IGC trading and performance, cannot imagine how notoriously manipulated all the cannabis/hemp related stocks!, but there is always a limit to what they can do and a Breakout out will smash and toast the MMs, shorties and everyone else is screwing up this stock...and the time is Now!..

Enjoy the ride, in my next post I will provide target prices, it will be juicy and nice!.

One thing I will never understand is HOW IS THIS STOCK TRADING SUCH ELEVATED VOLUME EVERY SINGLE DAY YET IS NEVER A TOPIC OF DISCUSSION ON ANY FORUMS?

How the hell does this stock trade so much in volume yet get hardly any conversation whatsoever?

Carl Icahn is investing

To understand the CEO you have to understand the Fraud Culture of India. https://www-dailyo-in.cdn.ampproject.org/v/s/www.dailyo.in/lite/variety/scams-nirav-modi-rotomac-fodder-scam-pnb/story/1/22537.html?amp_js_v=a6&_gsa=1&usqp=mq331AQKKAFQArABIIACAw%3D%3D#aoh=16295815347950&_ct=1629581554362&referrer=https%3A%2F%2Fwww.google.com&_tf=From%20%251%24s&share=https%3A%2F%2Fwww.dailyo.in%2Fvariety%2Fscams-nirav-modi-rotomac-fodder-scam-pnb%2Fstory%2F1%2F22537.html

Yep I agree..may consider buying ,a hundred shares I long term,a jyear or. More if I trsearch other patents for skin issues arthritis ,parkensens etc..will post result soon

It bounced at the open then fell for the remainder. Might see another bounce off 1.60's but 1.40-1.50 looks like better entry.

No bounce today..extra research shows igc had reverse 10 for 1 stock split.. in 2013…it’s been downhill except for couple spikes from “fake” news reports . plus given. their ultra high cost per employee..ie nonprofit for 4 years ago, I suggest owners and insiders are exceptionally poor manager or they are 99% dishonest and only see stock as a way to line their pockets..wow..am glad I only bought 150 shares..if it gets to $2.20 I will sell ASAP.Troytex in north Texas